Verge Genomics Gets $98M to Take ALS Drug to the Clinic

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

SQZ Shows Promise With HPV+ Cancer Vaccine in Early Solid Tumor Clinical Trial
Verge Genomics Strikes Deal with Lilly to Validate New Targets for ALS
What Can You Do With Genomics and AI? Alice Zhang on The Long Run